Authors
Elliot Israel, Vernon M Chinchilli, Jean G Ford, Homer A Boushey, Reuben Cherniack, Timothy J Craig, Aaron Deykin, Joanne K Fagan, John V Fahy, James Fish, Monica Kraft, Susan J Kunselman, Stephen C Lazarus, Robert F Lemanske, Stephen B Liggett, Richard J Martin, Nandita Mitra, Stephen P Peters, Eric Silverman, Christine A Sorkness, Stanley J Szefler, Michael E Wechsler, Scott T Weiss, Jeffrey M Drazen
Publication date
2004/10/23
Journal
The Lancet
Volume
364
Issue
9444
Pages
1505-1512
Publisher
Elsevier
Description
Background
The issue of whether regular use of an inhaled β2-adrenergic agonist worsens airflow and clinical outcomes in asthma is controversial. Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the β2-adrenergic receptor. However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial.
Methods
Patients with mild asthma, not using a controller medication, were enrolled in pairs matched for forced expiratory volume in 1 s (FEV1) according to whether they had the Arg/Arg (n=37; four of 41 matches withdrew before randomisation) or Gly/Gly (n=41) genotype. Regularly scheduled treatment with albuterol or placebo was given in a masked, cross-over design, for 16-week periods. During the study, as-needed …
Total citations
Scholar articles
E Israel, VM Chinchilli, JG Ford, HA Boushey… - The Lancet, 2004